AGIOS PHARMACEUTICALS, INC. - Common stock, par value $0.0001 per share (AGIO) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common stock, par value $0.0001 per share
Symbol
AGIO on Nasdaq
Shares outstanding
58,272,553
Price per share
$28.32
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
61,205,333
Total reported value
$1,666,178,548
% of total 13F portfolios
0%
Share change
-4,100,619
Value change
-$304,146,594
Number of holders
233
Price from insider filings
$28.32
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AGIOS PHARMACEUTICALS, INC. - Common stock, par value $0.0001 per share (AGIO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Farallon Capital Partners, L.P. 8.8% -11% $146,117,182 -$14,583,696 5,159,505 -9.1% Dapice Joshua J. 31 Dec 2025
BlackRock, Inc. 7.8% $150,100,362 4,513,170 BlackRock, Inc. 30 Jun 2025
STATE STREET CORP 5.3% $88,022,666 3,108,145 STATE STREET CORPORATION 31 Dec 2025
ARMISTICE CAPITAL, LLC 5.2% $85,979,520 3,036,000 Armistice Capital, LLC 31 Dec 2025
Paradigm Biocapital Advisors LP 4.9% -6% $115,344,498 -$6,198,499 2,873,555 -5.1% Paradigm BioCapital Advisors LP 30 Sep 2025

As of 31 Dec 2025, 233 institutional investors reported holding 61,205,333 shares of AGIOS PHARMACEUTICALS, INC. - Common stock, par value $0.0001 per share (AGIO). This represents 105% of the company’s total 58,272,553 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of AGIOS PHARMACEUTICALS, INC. - Common stock, par value $0.0001 per share (AGIO) together control 79% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 9.6% 5,594,353 -0.19% 0% $152,278,288
BlackRock, Inc. 9% 5,235,429 +15% 0% $142,508,377
FARALLON CAPITAL MANAGEMENT LLC 8.9% 5,159,505 -11% 0.81% $140,441,726
STATE STREET CORP 5.3% 3,108,145 +37% 0% $84,603,707
ARMISTICE CAPITAL, LLC 5.2% 3,036,000 +297% 2% $82,639,920
Erste Asset Management GmbH 4.8% 2,804,900 +1.4% 0.64% $76,343,084
D. E. Shaw & Co., Inc. 3.2% 1,837,186 +400% 0.04% $50,008,203
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 2.9% 1,701,409 0% 0.07% $46,312,000
GEODE CAPITAL MANAGEMENT, LLC 2.4% 1,413,538 -0.2% 0% $38,483,546
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 2.3% 1,360,730 +38% 0.04% $37,039,000
CITADEL ADVISORS LLC 2.3% 1,348,968 +174% 0.02% $36,718,909
MPM BIOIMPACT LLC 2.2% 1,303,373 4.1% $35,477,813
Frazier Life Sciences Management, L.P. 2.2% 1,279,754 0% 0.94% $34,834,904
GW&K Investment Management, LLC 2.1% 1,207,301 +42% 0.28% $32,863,000
TCG Crossover Management, LLC 2% 1,181,841 -17% 1.1% $32,169,712
SUSQUEHANNA INTERNATIONAL GROUP, LLP 2% 1,142,432 0.04% $31,096,999
JANE STREET GROUP, LLC 1.9% 1,121,050 +184% 0.04% $30,514,981
GOLDMAN SACHS GROUP INC 1.8% 1,033,974 +28% 0% $28,144,772
DIMENSIONAL FUND ADVISORS LP 1.7% 1,004,341 -1.7% 0.01% $27,338,360
MORGAN STANLEY 1.5% 894,036 +114% 0% $24,335,668
Rock Springs Capital Management LP 1.4% 799,163 -17% 1.1% $21,753,217
Capital International Investors 1.2% 703,865 0% $19,159,205
PRICE T ROWE ASSOCIATES INC /MD/ 1.1% 637,886 -62% 0% $17,364,000
Balyasny Asset Management L.P. 1.1% 635,069 +28% 0.03% $17,286,578
SCS Capital Management LLC 1% 598,765 0% 0.17% $16,298,383

Institutional Holders of AGIOS PHARMACEUTICALS, INC. - Common stock, par value $0.0001 per share (AGIO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 61,205,333 $1,666,178,548 -$304,146,594 $27.22 233
2025 Q3 63,494,342 $2,545,893,773 +$81,770,154 $40.14 217
2025 Q2 61,683,672 $2,051,725,997 +$65,237,829 $33.26 211
2025 Q1 59,963,279 $1,757,322,194 -$10,187,060 $29.30 216
2024 Q4 59,832,436 $1,966,429,716 +$37,958,970 $32.86 221
2024 Q3 58,096,571 $2,582,267,784 -$8,181,474 $44.43 204
2024 Q2 58,132,966 $2,506,935,894 -$125,225,015 $43.12 203
2024 Q1 61,946,791 $1,811,267,450 +$89,235,062 $29.24 183
2023 Q4 59,884,422 $1,333,701,271 +$15,853,345 $22.27 167
2023 Q3 59,110,077 $1,463,036,585 -$8,921,651 $24.75 142
2023 Q2 59,366,269 $1,679,785,246 +$16,420,594 $28.32 150
2023 Q1 58,996,438 $1,355,139,176 -$9,985,145 $22.97 161
2022 Q4 59,442,573 $1,669,125,079 +$45,133,345 $28.08 156
2022 Q3 57,972,960 $1,639,524,356 -$46,396,034 $28.28 155
2022 Q2 59,017,906 $1,308,562,484 -$21,425,021 $22.17 143
2022 Q1 59,895,743 $1,743,443,247 +$19,219,573 $29.11 146
2021 Q4 59,210,281 $1,947,305,194 -$73,787,635 $32.87 148
2021 Q3 60,890,488 $2,810,077,563 -$244,072,957 $46.15 157
2021 Q2 65,926,694 $3,632,531,095 +$51,380,893 $55.11 179
2021 Q1 65,233,267 $3,366,007,585 +$56,136,770 $51.64 168
2020 Q4 64,981,734 $2,817,090,446 -$19,419,372 $43.33 189
2020 Q3 65,869,834 $2,304,359,620 -$101,763,130 $35.00 206
2020 Q2 67,492,943 $3,609,431,770 -$76,258,753 $53.48 205
2020 Q1 69,390,256 $2,461,883,479 +$6,215,421 $35.48 188
2019 Q4 69,034,713 $3,296,545,303 +$348,129,625 $47.75 192
2019 Q3 61,888,248 $2,005,330,307 +$38,059,098 $32.40 180
2019 Q2 60,668,045 $3,025,896,532 +$157,762,312 $49.88 182
2019 Q1 60,134,445 $4,055,728,260 +$162,774,480 $67.44 191
2018 Q4 58,006,486 $2,674,145,349 +$50,031,635 $46.11 182
2018 Q3 55,625,309 $4,289,793,406 +$92,816,537 $77.12 199
2018 Q2 54,418,427 $4,583,658,355 -$33,625,899 $84.23 207
2018 Q1 54,830,882 $4,483,993,749 +$716,755,603 $81.78 192
2017 Q4 46,986,627 $2,686,172,197 +$50,530,934 $57.17 173
2017 Q3 46,056,523 $3,074,218,539 +$17,986,293 $66.75 168
2017 Q2 46,127,851 $2,373,318,886 +$325,571,290 $51.45 164
2017 Q1 40,972,190 $2,392,699,790 +$240,606,903 $58.40 154
2016 Q4 39,019,883 $1,628,427,134 +$42,873,951 $41.73 154
2016 Q3 37,828,945 $1,997,518,488 +$255,912,326 $52.82 160
2016 Q2 33,999,654 $1,424,491,193 +$19,274,497 $41.89 150
2016 Q1 33,779,727 $1,371,223,373 +$17,925,029 $40.60 151
2015 Q4 33,010,570 $2,143,167,128 +$96,156,802 $64.92 141
2015 Q3 31,391,017 $2,215,769,820 +$82,761,834 $70.59 149
2015 Q2 30,124,596 $3,347,682,014 +$244,304,306 $111.14 159
2015 Q1 27,958,847 $2,636,827,051 -$36,991,648 $94.30 149
2014 Q4 27,657,103 $3,098,842,918 +$394,968,566 $112.04 142
2014 Q3 24,482,713 $1,502,054,443 +$81,527,891 $61.35 119
2014 Q2 23,591,425 $1,080,804,790 +$140,019,435 $45.82 99
2014 Q1 20,545,950 $804,373,483 +$93,802,312 $39.15 73